Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies - PubMed (original) (raw)
Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies
M Kelliher et al. Neuroscience. 1999.
Abstract
Investigation of the integrity of the ryanodine receptor in Alzheimer's disease is important because it plays a critical role in the regulation of calcium release from the endoplasmic reticulum in brain, impairment of which is believed to contribute to the pathogenesis of Alzheimer's disease. The present study compared ryanodine receptor levels and their functional modulation in particulate fractions from control and Alzheimer's disease temporal cortex, occipital cortex and putamen. Relationships between ryanodine receptor changes and the progression of Alzheimer's disease pathology were determined by examining autoradiographic [3H]ryanodine binding in entorhinal cortex/anterior hippocampus sections from 22 cases that had been staged for neurofibrillary changes and beta-amyloid deposition. A significant (P < 0.02) 40% decrease in the Bmax for [3H]ryanodine binding and significantly higher IC50 values for both magnesium and Ruthenium Red inhibition of [3H]ryanodine binding were detected in Alzheimer's disease temporal cortex particulate fractions compared to controls. Immunoblot analyses showed Type 2 ryanodine receptor holoprotein levels to be decreased by 20% (P < 0.05) in these Alzheimer's disease cases compared to controls. No significant differences were detected in [3H]ryanodine binding comparing control and Alzheimer's disease occipital cortex or putamen samples. The autoradiography study detected increased [3H]ryanodine binding in the subiculum, CA2 and CA1 regions in cases with early (stage I-II) neurofibrillary pathology when compared to Stage 0 cases. Analysis of variance of data with respect to the different stages of neurofibrillary pathology revealed significant stage-related declines of [3H]ryanodine binding in the subiculum (P < 0.02) with trends towards significant decreases in CA1, CA2 and CA4. Post-hoc testing with Fisher's PLSD showed significant reductions (74-94%) of [3H]ryanodine binding in the subiculum, and CA1-CA4 regions of the late isocortical stage (V-VI) cases compared to the early entorhinal stage I-II cases. [3H]Ryanodine binding also showed significant declines with staging for beta-amyloid deposition in the entorhinal cortex (P < 0.01) and CA4 (P < 0.05) with trends towards a significant decrease in the dentate gyrus. We conclude that alterations in ryanodine receptor binding and function are very early events in the pathogenesis of Alzheimer's disease, and may be fundamental to the progression of both neurofibrillary and beta-amyloid pathologies.
Similar articles
- Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology.
Kurumatani T, Fastbom J, Bonkale WL, Bogdanovic N, Winblad B, Ohm TG, Cowburn RF. Kurumatani T, et al. Brain Res. 1998 Jun 15;796(1-2):209-21. doi: 10.1016/s0006-8993(98)00347-3. Brain Res. 1998. PMID: 9689471 - Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
García-Jiménez A, Cowburn RF, Ohm TG, Bogdanovic N, Winblad B, Fastbom J. García-Jiménez A, et al. Brain Res. 1999 Dec 11;850(1-2):104-17. doi: 10.1016/s0006-8993(99)02111-3. Brain Res. 1999. PMID: 10629754 - Evolution of the neuropathology of Alzheimer's disease.
Braak H, Braak E. Braak H, et al. Acta Neurol Scand Suppl. 1996;165:3-12. doi: 10.1111/j.1600-0404.1996.tb05866.x. Acta Neurol Scand Suppl. 1996. PMID: 8740983 Review. - Amyloid-beta, tau, and dementia.
Takashima A. Takashima A. J Alzheimers Dis. 2009;17(4):729-36. doi: 10.3233/JAD-2009-1090. J Alzheimers Dis. 2009. PMID: 19542626 Review.
Cited by
- Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease.
Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, Wicks J, Richardson JC, Conklin V, Cameransi BG, Stutzmann GE. Chakroborty S, et al. PLoS One. 2012;7(12):e52056. doi: 10.1371/journal.pone.0052056. Epub 2012 Dec 21. PLoS One. 2012. PMID: 23284867 Free PMC article. - Control of intracellular calcium signaling as a neuroprotective strategy.
Duncan RS, Goad DL, Grillo MA, Kaja S, Payne AJ, Koulen P. Duncan RS, et al. Molecules. 2010 Mar 3;15(3):1168-95. doi: 10.3390/molecules15031168. Molecules. 2010. PMID: 20335972 Free PMC article. Review. - Development and implementation of a high-throughput compound screening assay for targeting disrupted ER calcium homeostasis in Alzheimer's disease.
Honarnejad K, Daschner A, Giese A, Zall A, Schmidt B, Szybinska A, Kuznicki J, Herms J. Honarnejad K, et al. PLoS One. 2013 Nov 15;8(11):e80645. doi: 10.1371/journal.pone.0080645. eCollection 2013. PLoS One. 2013. PMID: 24260442 Free PMC article. - Alterations of the Endoplasmic Reticulum (ER) Calcium Signaling Molecular Components in Alzheimer's Disease.
Chami M, Checler F. Chami M, et al. Cells. 2020 Dec 1;9(12):2577. doi: 10.3390/cells9122577. Cells. 2020. PMID: 33271984 Free PMC article. Review. - Presenilins regulate calcium homeostasis and presynaptic function via ryanodine receptors in hippocampal neurons.
Wu B, Yamaguchi H, Lai FA, Shen J. Wu B, et al. Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15091-6. doi: 10.1073/pnas.1304171110. Epub 2013 Aug 5. Proc Natl Acad Sci U S A. 2013. PMID: 23918386 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous